ILT3/CD85k/LILRB4 Antibody (1057706) [Unconjugated]

LILRB4/CD85k/ILT3 was detected in immersion fixed Transfected & Wild Type HEK293 Human Embryonic Kidney Cell Line using Mouse Anti-Human LILRB4/CD85k/ILT3 Monoclonal Antibody (Catalog # MAB24252) at 3 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Mouse IgG Secondary Antibody (red; Catalog # NL007) and counterstained with DAPI (blue). Specific staining was localized to Cytoplasm. View our protocol for Fluorescent ICC Staining of Cells on Coverslips.

PBMCs with CD123 costain were stained with Mouse Anti-Human IL-3R alpha/CD123 PE‑conjugated Monoclonal Antibody (Catalog # FAB301P) and either (A) Mouse Anti-Human LILRB4/CD85k/ILT3 Monoclonal Antibody (Catalog # MAB24252) or (B) Mouse IgG2A Isotype Control (Catalog # MAB003) followed by Allophycocyanin-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0101B). View our protocol for Staining Membrane-associated Proteins.

• Reactivity: Hu
• Applications: Flow, ICC/IF
• Clone: 1057706
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated

ILT3/CD85k/LILRB4 Antibody (1057706) [Unconjugated] Summary

• Immunogen: Mouse myeloma cell line, NS0-derived recombinant human LILRB4/CD85k/ILT3 protein
  Pro17-His257
  Accession # ABM86208
• Specificity: Detects human LILRB4/CD85k/ILT3 in direct ELISA.
• Source: N/A
• Isotype: IgG2a
• Clonality: Monoclonal
• Host: Mouse
• Purity Statement: Protein A or G purified from hybridoma culture supernatant

Applications/Dilutions

• Dilutions:
  • Flow Cytometry 0.25 ug/10^6 cells
  • Immunocytochemistry 3-25 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for ILT3/CD85k/LILRB4 Antibody (1057706) [Unconjugated]

• CD85 antigen-like family member K
• CD85k antigen
• CD85k
• HM18
• ILT3
• ILT-3
• ILT3CD85K
• leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains)
• LILRB4
• LIR5
• LIR5LILRB5
• LIR-5subfamily B, member 4
• member 4

Background

ILT3, also known as CD85k and LIR-5, is an approximately 60 kDa transmembrane glycoprotein that negatively regulates immune cell activation (1). Mature human ILT3 consists of a 238 amino acid (aa) extracellular domain with two Ig-like domains, a 21 aa transmembrane segment, and a 168 aa cytoplasmic domain with 3 immunoreceptor tyrosine-based inhibitory motifs (ITIM) (2). Alternative splicing of human ILT3 generates an isoform that lacks the first ITIM and a secreted isoform that circulates in the serum of cancer patients (3, 4). ILT3 is expressed on dendritic cells (DC), monocytes, macrophages, and vascular endothelial cells (EC) (2, 5, 6). Ligation of ILT3 triggers ITIM-mediated inhibition of cell-activating signaling, leading to enhanced immune tolerance and reduced allogeneic graft rejection (2, 4, 7, 8). Soluble ILT3 induces the differentiation of CD8⁺ T suppressor cells (Ts) that can inhibit the effector functions of CD4⁺ Th cells and CD8⁺ CTL (4, 7, 9). In turn, CD8⁺ Ts cells induce ILT3 up-regulation and a tolerogenic phenotype in monocytes, DC, and EC (5, 6, 8, 10, 11).

1. Vlad, G. et al. (2010) Int. Rev. Immunol. 29:119.
2. Cella, M. et al. (1997) J. Exp. Med. 185:1743.
3. Heinzmann, A. et al. (2000) Eur. J. Immunogenet. 27:121.
4. Suciu-Foca, N. et al. (2007) J. Immunol. 178:7432.
5. Gleissner, C.A. et al. (2007) Eur. J. Immunol. 37:177.
6. Manavalan, J.S. et al. (2004) Int. Immunol. 16:1055.
7. Vlad, G. and N. Suciu-Foca (2012) Exp. Mol. Pathol. 93:294.
8. Chang, C.C. et al. (2002) Nat. Immunol. 3:237.
9. Vlad, G. et al. (2006) Int. Immunopharmacol. 6:1889.
10. Manavalan, J.S. et al. (2003) Transpl. Immunol. 11:245.
11. Brenk, M. et al. (2009) J. Immunol. 183:145.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Uniprot:
  • ABM86208()